Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Immune regeneration: implications for cancer immunotherapy and beyond
Steven L. Reiner
Steven L. Reiner
View: Text | PDF
Review

Immune regeneration: implications for cancer immunotherapy and beyond

  • Text
  • PDF
Abstract

Cancer care is being transformed by therapies leveraging T lymphocytes to attack tumor cells. In parallel, recent basic discoveries have converged into a framework of lymphocyte-dependent immunity as a regenerative process that is sometimes outstripped by high-level engagement. In a stem cell–like fashion, selected T cells must balance mutually opposing demands of differentiation and self-renewal. Activating versus inhibitory signals to T cells instruct opposing cell metabolism, linked to alternative cell fates that arise in sibling cells through lopsided information transfer. Emerging studies indicate that durable immunotherapy response may be limited by the abundance of self-renewing T cells. Leveraging of basic discoveries of regenerative signaling to bolster sustained, stem-like output of freshly differentiated T cells is offering new strategies to overcome cancer immunotherapy resistance. Lymphocyte regeneration may also sustain harmful autoimmune attack. Undercutting the self-renewal of pathogenic clones may thus emerge as a therapeutic strategy for autoimmune diseases.

Authors

Steven L. Reiner

×

Figure 4

Successful and insufficient immunity from a regenerative perspective.

Options: View larger image (or click on image) Download as PowerPoint
Successful and insufficient immunity from a regenerative perspective.
Al...
All responses are triggered by sufficient antigen plus costimulatory signals (lightning bolt, row 1). Successful immune regeneration during acute infection and upon its resolution (row 2) illustrates the facultative (threat-dependent) nature of the progenitor and differentiated stages. Lifelong control of persistent low-level infection is analogous to perpetuation of autoimmune attack (row 3), with ongoing impetus for regeneration. Rows 4–6 depict vertical downward progression of tumor growth or increasing viral burden alongside hypothetical regenerative status without treatment (left) or with PD-1 blockade (right). The high incidence of immunotherapy resistance is probably related to progressive loss of self-renewing T cells as disease burden progresses. Optimal outcomes are more likely to be achieved when treatment is initiated earlier or with interventions that could prolong the window of self-renewing T cell abundance. Not shown is potential benefit of the arising of new neoantigens, which would appear as new red clones being deposited into the left-hand well. PD-1 blockade is depicted as lowering the activation energy and catalyzing greater division and differentiation from self-renewing cells while they persist. Adapted from ref. 134 with permission.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts